- Home
- IBRX vs JANX Comparison
IBRX vs JANX Comparison
Compare IBRX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- JANX
- Stock Information
- Founded
- IBRX 2014
- JANX 2017
- Country
- IBRX United States
- JANX United States
- Employees
- IBRX N/A
- JANX N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- IBRX Health Care
- JANX Health Care
- Exchange
- IBRX Nasdaq
- JANX Nasdaq
- Market Cap
- IBRX 1.9B
- JANX 2.2B
- IPO Year
- IBRX N/A
- JANX 2021
- Fundamental
- Price
- IBRX $3.42
- JANX $36.01
- Analyst Decision
- IBRX Strong Buy
- JANX Strong Buy
- Analyst Count
- IBRX 3
- JANX 11
- Target Price
- IBRX $13.58
- JANX $83.09
- AVG Volume (30 Days)
- IBRX 6.0M
- JANX 852.9K
- Earning Date
- IBRX 03-18-2025
- JANX 03-07-2025
- Dividend Yield
- IBRX N/A
- JANX N/A
- EPS Growth
- IBRX N/A
- JANX N/A
- EPS
- IBRX N/A
- JANX N/A
- Revenue
- IBRX $7,332,000.00
- JANX $13,049,000.00
- Revenue This Year
- IBRX $2,359.81
- JANX $39.66
- Revenue Next Year
- IBRX $808.10
- JANX N/A
- P/E Ratio
- IBRX N/A
- JANX N/A
- Revenue Growth
- IBRX 1218.71
- JANX 54.12
- 52 Week Low
- IBRX $2.28
- JANX $14.84
- 52 Week High
- IBRX $10.53
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- IBRX 52.26
- JANX 34.78
- Support Level
- IBRX $3.35
- JANX $36.13
- Resistance Level
- IBRX $4.27
- JANX $38.13
- Average True Range (ATR)
- IBRX 0.31
- JANX 2.52
- MACD
- IBRX 0.04
- JANX 0.08
- Stochastic Oscillator
- IBRX 29.17
- JANX 5.71
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.